

Fractional Laser Skin Resurfacing with SmartXide DOT. Initial Results.

Anne Le Pillouer-Prost, Department of Dermatology, Clairval Hospital, Marseilles, France
 Nicola Zerbinati, Department of Dermatology, University of Insubria, Varese, Italy

INTRODUCTION

The natural ageing process together with exposure to the sun and pollution leads to a gradual deterioration of the skin's structure and function. This is mainly evident at the level of the epidermis and the upper papillary dermis, with a tissue laxity and skin that appears more lined, often accompanied by telangiectasias, wrinkles, and dark spots^{1,2}.

Resurfacing with ultra-pulsed CO₂ has always been considered the first choice of treatment for rhytids and photo-damaged facial skin³⁻¹². However, due to the lengthy recovery times and frequent complications^{13,14}, very few patients agree to undergo this type of operation^{15,16}. Besides the usual recovery time required for oedema, burning, scabs and erythema which may often last for months^{17,18}, there is also a high incidence of complications connected with hyper- and hypo-pigmentation, scarring, HSV infection (fig. 1), outbreaks of acne (fig.2), milia formation, and dermatitis¹⁹⁻²⁴.



Fig. 1 and 2 : Cases of HSV infection and outbreaks of acne, after traditional resurfacing with pulsed CO₂ laser.

Over recent years, the market has therefore been orientated towards less invasive and less problematic systems and methods. This has led to a wide-scale production of a myriad of non-ablative devices for reducing wrinkles and improving photo-damaged skin with the consequent passing over from "skin resurfacing" to "skin rejuvenation".

However, a critical review of the literature inherent to these methods has revealed that in terms of efficacy, none of the results obtained with these non-ablative methods can be compared with the resurfacing results achieved with the CO₂ laser²³⁻²⁷. Moreover, these types of treatment are usually quite expensive for the patient, the devices themselves are also costly for the medical practitioners, and the results obtained are not always satisfactory.

This situation has stimulated the search for new methods and protocols that are more efficient in combining quick recovery and minimal post-op risks with greater treatment efficacy.

The advent of Fractional Photothermolysis, initially introduced with non-ablative methods, has given rise to the development of a new method that manages to effectively combine all the needs of both medical practitioners and patients, and namely, the Fractional Laser Skin Resurfacing (FLSR) with CO₂ laser²⁸⁻³⁰.

Various CO₂ lasers with fractioned emission are currently available on the market. Despite the fact that all these systems are based on the same principles, they present significant differences with regard to output power, dwell-time, distance between the dots, varying scanner shapes and the laser beam profile. These differences may produce clinical results that differ greatly between one device and another.

MATERIALS AND METHOD

A CO₂ laser system called SmartXide (Deka, Florence, Italy) that works with a scanner in DOT mode has been used in each of the cases presented in this article. The SmartXide DOT system, which is a CO₂ laser with 30-watt maximum power in CW, is capable of emitting high energies in pulsed mode. In order to carry out fractioned treatments, a new pulsed emission mode called SmartPulse has also been developed. The first part of this new mode consists of a high peak power pulse that allows for rapid ablation of the epidermis and the first layers of the derma, while the second part of the pulse has low peak power allowing for targeted heating of the deeper areas of the skin (Fig.3).




Fig. 3: SmartPulse laser emission.

The laser beam is focussed and positioned on the adjacent dots by means of a special scanner (DOT mode). The user is also able to set the most important features of the emission, such as power, dwell-time, shape and size of the area to be treated, and the distance between the dots.

All patients enrolled in this preliminary trial were subjected to one or more treatments with the SmartXide DOT system. The interval between the sessions varied between 20 and 40 days. The objective of this initial trial was to highlight the versatility of the SmartXide DOT system in the treatment of wrinkles, skin laxity, epidermal and dermal pigmentation (including melasma), and hypertrophic scars. Additional trials are underway for enabling a careful examination of each of these treatments on a higher number of case studies. The results have only been examined visually with a follow-up varying between one month and three months after the last treatment.

RESULTS

The SmartXide DOT fractionated system has been used in this trial for verifying its effectiveness in various treatments at both an epidermal and dermal level. The first case concerns the treatment of acne scars on the cheeks of a 24 year-old girl. Already after only one treatment a reduction in the fibrous part of the scars was observed as well as a decrease in the associated pigmentation and dilatation of the pores. The parameters used were 30 W, a distance of 1,000 μm between spots, and 2 ms dwell time, corresponding to a dose of 3.3 J/cm² (Fig.4).



Fig. 4: Acne scars. Pre and post 1 session with Smartxide DOT 30W, 1,000 μm distance between spots and 2 ms dwell time.

In the second case a 32 year-old man was treated for a keloid on his chest. Aggressive treatments were also preferred in this case (30 W, 800 μm , 2 ms and a dose of 4.5 J/cm²) due to the marked fibrotic component. After two treatments 30 days apart the results were totally satisfactory (Fig.5).

In the cases of pigmentation, the treatment must have lower fluences, such as 15 W, 500 μm and 300 μs , corresponding to a fluence of only 0.6 J/cm². All these cases gave more than satisfactory results although in the case of the melasma the sessions naturally had to be repeated 5 or 6 times (Fig. 6,



Fig. 5: Keloid on chest. Pre and post 2 sessions with Smartxide DOT 30W, 800 μm distance between spots and 2 ms dwell time.



Fig. 6: Epidermal pigmented lesion. Pre and post 1 session with Smartxide DOT 15W, 500 μm distance between spots and 300 μs dwell time.



Fig. 7 and 8: Melasma. Pre and post 5 sessions (Fig.7) or 4 sessions (Fig.8) with Smartxide DOT 15W, 1000 μm distance between spots and 300 μs dwell time.

7 and 8). The fluence was increased to 7.1 J/cm² (30 W, 300 μm , 1 ms) when the lesion showed considerable thickening, as illustrated in Fig.9.

In the case of skin lines, the best treatment was obtained using an intermediate fluence (30 W, 500 μm , 1 ms, 4.1 J/cm²) for as many as 4 sessions. In



Fig. 9: Epidermal Nevus. Pre and post 1 session with Smartxide DOT 30W, 300 μm distance between spots and 1 ms dwell time.



Fig. 10 and 11: Perilabial (Fig.10) and periocular (Fig 11) wrinkles. Pre and post 1 session with Smartxide DOT 30W, 500 μm distance between spots and 1 ms dwell time.

this case it was possible to keep the erythema under control, limiting it to a few days. In all cases the results were excellent from both a dermatological and a cosmetological point of view (Fig. 10 and 11).

DISCUSSION

The SmartXide CO₂ laser allows for carrying out FLSR treatment by using the scanner in DOT mode. With FLSR the epithelial damage caused is less dramatic than that caused by the traditional ablative techniques. A part of the tissue remains intact during the treatment and acts like a natural bandage. The skin healing process is much faster compared to that with the Traditional Laser Skin Resurfacing (TLSR) techniques (Fig.12 and 13). The areas treated are in fact surrounded by portions of intact tissue that help heal the damaged areas by providing new cells. The following downtime is therefore considerably reduced. Moreover, erythema is moderate and allows the patient to




Fig. 12 and 13: Comparison between TLSR (sOW, Standard Mode, 200 μs) and FLSR (30W, DOT Mode, 2 ms, 1000 μm) effect. 4 days (Fig. 12) and 1 month (Fig. 13) after the test.



Fig. 14: Erythema 24 hours after DOT treatment with 30W power, spacing 1000 μm spacing and 2 ms dwell time.

apply makeup immediately after the operation (Fig.14). As illustrated in Fig.15, the procedure the patient has to undergo is far better in the case of FLSR treatments compared TLSR. The re-epithelisation is greatly accelerated thanks to the limited epidermal damage and also begins on the first day. This aspect is fundamental for limiting the serious complications associated with every epidermal re-epithelisation process. The shorter the time required for forming a new epidermis, the lower the risk of bacterial or viral infections of the




Fig. 15: Recovery process comparison between TLSR and FLSR.

exposed derma. Another remarkable advantage is the reduction of erythema associated with the treatment, both in terms of absolute intensity and duration. This aspect is vitally important for reducing the period of social exclusion imposed by the other traditional methods.

CONCLUSION

The SmartXide DOT CO₂ laser has proved to be an extremely versatile instrument in dermatology. The results obtained are excellent and in nearly all cases have given rise to full patient satisfaction. The wide range of possibilities offered by modulating the laser scanner allows for adapting the treatment to the different features and expectations of each individual patient.

By using the DOT mode, downtime is minimal and the moderate erythema allows the patient to use appropriate makeup immediately after the operation.

The incidence of the typical side effects of TLSR is negligible provided the patient follows the simple recommendations given after the operation.

We established in this preliminary trial that the dose ranges differ in the case of superficial pigmented lesions (equal to or less than 1.0 J/cm²), wrinkles (from 2 to 5 J/cm²) and pronounced fibrotic lesions (over 6 J/cm²).

For all these reasons, the treatment with SmartXide DOT represents a valid aid in dermatology without any of the negative complications involved in the conventional ablative and non-ablative systems.

ACKNOWLEDGEMENTS

The authors wish to thank Eng. Lara Ronconi from El.En. SpA for her valuable contribution in drafting this paper.

REFERENCES

1. Taylor CR et al: Photoaging/photodamage and photoprotection. *J Am Acad Dermatol* 22:1, 1990
2. Lavker RM: Cutaneous aging: Chronological versus photoaging, in *Photodamage*, edited by Gilchrist BA. Cambridge, MA, Blackwell Science, 1995, p 123
3. Ratner D, Tse Y, Marchell N, Goldman MP, Fitzpatrick RE, Fader DJ. Cutaneous laser resurfacing. *J Am Acad Dermatol*. 1999; 41:365-89.
4. Manuskatti W, Fitzpatrick RE, Goldman MP. Long-term effectiveness and side effects of carbon dioxide laser resurfacing for photoaged facial skin. *J Am Acad Dermatol*. 1999;40:401-11.
5. Fitzpatrick RE, Goldman MP, Satur NM, Tope WD. Pulsed carbon dioxide laser resurfacing of photo-aged facial skin. *Arch Dermatol* 1996;132:395-402.
6. Schwartz RJ, Burns AJ, Rohrich RJ, Barton FE, Byrd HS. Long term assesment of CO₂ facial laser resurfacing: Aesthetic results and complications. *Plast Reconstr Surg*. 1999; 103:592-601.
7. Hamilton MM. Carbon dioxide laser resurfacing. *Facial Plast Surg Clin North Am*. 2004;12:289-95.
8. Lent WM, David LM. Laser resurfacing: a safe and predictable method of skin resurfacing. *J Cutan Laser Ther*. 1999;1:87-94.
9. Airan LE, Hruza G. Current lasers in skin resurfacing. *Facial Plast Surg Clin North Am*. 2002;10:87-101.
10. Fitzpatrick RE. CO₂ laser resurfacing. *Dermatol Clin*.2001;19:443-51.
11. Fitzpatrick RE. Maximizing benefits and minimizing risk with CO₂ laser resurfacing. *Dermatol Clin*. 2002;20:77-86.
12. Hruza GJ, Dover JS. Laser skin resurfacing. *Arch Dermatol* 1996;132:451-455.
13. Bernstein L, Kauvar A, Grossman M, Geronemus R. The short and long term side effects of carbon dioxide laser resurfacing. *Dermatol Surg* 1997;23:519-525.
14. Alster T, Hirsch R. Single-pass CO₂ laser skin resurfacing of light and dark skin: Extended experience with 52 patients.*J Cosmet Laser Ther* 2003;5:39-42.
15. Trelles MA, Mordon S, Svaasand LQ, et al. The origin and role of erythema after carbon dioxide laser resurfacing: a clinical and histologic study. *Dermatol Surg*. 1998;24:25-30.
16. Burkhardt BR, Maw R. Are more passes better? safety versus efficacy with the pulsed CO₂ laser. *Plast Reconstr Surg*. 1997;99:1531-1534.
17. Sullivan SA, Dailey RA. Complications of laser resurfacing and their management. *Ophthal Plast Reconstr Surg*.2000;16:417-26.
18. Berwald C, Levy JL, Magalon G. Complications of the resurfacing laser: Retrospective study of 749 patients. *Ann Chir Plast Esthet*. 2004;49:360-5.
19. Alster TS. Cutaneous resurfacing with CO₂ and erbium: YAG lasers: preoperative, intraoperative, and postoperative considerations. *Plast Reconstr Surg*. Feb 1999;103(2):619-32; discussion 633-4.
20. Alster TS. Side effects and complications of laser surgery. In *Alster TS: Manual of Cutaneous Laser Techniques*, ed 2. Philadelphia, Lippinc. 2000;pp 175-187.
21. Alster TS, Lupton JR. Treatment of complications of laser skin resurfacing. *Arch Facial Plast Surg*. Oct-Dec 2000;2(4):279-84.
22. Sriprachya-Anunt S, Fitzpatrick RE, Goldman MP, Smith SR. Infections complicating pulsed carbon dioxide laser resurfacing for photoaged facial skin. *Dermatol Surg*. 1997;23:527-36.
23. Nanni CA, Alster TS. Complications of carbon dioxide laser resurfacing. An evaluation of 500 patients. *Dermatol Surg* 1998;24:315-320.
24. Sadick NS. Update on non-ablative light therapy for rejuvenation: A review. *Lasers Surg Med*. 2003;32:120-8.
25. Williams EF III, Dahiya R. Review of nonablative laser resurfacing modalities. *Facial Plast Surg Clin North Am*. 2004;12:305-10.
26. Grema H, Greve B, Raulin C. Facial rhytides - subsurfacing or resurfacing? A review. *Lasers Surg Med*. 2003;32:405-12.
27. Bjerring P. Photorejuvenation - an overview. *Med LaserAppl*. 2004;19:186-95.
28. Matteo Tretti Clementoni, Patrizia Gilardino, Gabriele F. Muti, Daniela Beretta, Rossana Schianch. Non sequential fractional ultrapulsed CO₂ resurfacing of photoaged skin. *J Cosmc and Laser Ther*, 2007;9(4):218-22.
29. Hantash BM, Bedi VP, Chan KF, Zachary CB. Ex vivo histological characterization of a novel ablative fractional resurfacing device. *Laser Surg Med*. 2007;39:87-95.
30. Hantash BM, Bedi VP, Kapadia B, Rahman Z, Jiang K, Tanner H, Chan KF, Zachary CB. In vivo histological evaluation of a novel ablative fractional device. *Laser Surg Med*. 2007;39:96-107.